{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:44Z","timestamp":1791924764382,"version":"4.3.4"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Dupilumab-associated ocular surface disease (DAOSD) is one of the most common adverse events associated with dupilumab (an anti-interleukin-4-receptor-alpha monoclonal antibody) during the treatment of patients with atopic dermatitis (AD). However, it rarely occurs in patients with bronchial asthma or chronic rhinosinusitis with nasal polyps. Adequate understanding of DAOSD is important for proper diagnosis and appropriate ophthalmic intervention. The aim of this review was to summarize and discuss the clinical characteristics and management of DAOSD in Japan. The pathogenesis of DAOSD can be explained by the dry eye disease, upregulated T helper 17 and 22 cells, and\n                    <jats:italic>Demodex<\/jats:italic>\n                    theories. The main symptoms of DAOSD are irritation\/pain, redness, pruritus, discharge, and light sensitivity. Patients with AD and DAOSD as an adverse event develop various types of ocular surface disease, including blepharitis, blepharoconjunctivitis, conjunctivitis, keratoconjunctivitis, and keratitis. In ophthalmologic practice, to diagnose and treat DAOSD, physicians must understand the condition of the patient, make a differential diagnosis of conjunctivitis, determine concurrent dry eye, and assess DAOSD severity. Red flags for ophthalmologic intervention have been reported by organizations and institutions in various countries, which have highlighted the need for appropriate ophthalmologic intervention. Treatment of DAOSD involves topical treatments with artificial tears, antiallergic drugs, corticosteroids, and immunosuppressive drugs. In conclusion, patients with severe DAOSD require ophthalmologic intervention, and clinical collaboration between ophthalmologists and dermatologists is crucial for patients with AD during dupilumab treatment. This review can assist ophthalmologists in their daily practice and in their management of patients with DAOSD.\n                  <\/jats:p>","DOI":"10.1007\/s10384-025-01299-9","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:56:59Z","timestamp":1763704619000},"page":"1-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical characteristics and management of dupilumab-associated ocular surface disease in Japan"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8957-3312","authenticated-orcid":false,"given":"Jun","family":"Shoji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Ebihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"1299_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","volume":"77","author":"M Shirley","year":"2017","unstructured":"Shirley M. Dupilumab. First global approval. Drugs. 2017;77:1115\u201321.","journal-title":"Drugs"},{"key":"1299_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","volume":"104","author":"Y Nahum","year":"2020","unstructured":"Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol. 2020;104:776\u20139.","journal-title":"Br J Ophthalmol"},{"key":"1299_CR3","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1097\/ICO.0000000000002866","volume":"41","author":"T Felfeli","year":"2022","unstructured":"Felfeli T, Georgakopoulos JR, Jo CE, Minouni M, Piguet V, Drucker AM, et al. Prevalence and characteristics of dupilumab-induced ocular surface disease in adults with atopic dermatitis. Cornea. 2022;41:1242\u20137.","journal-title":"Cornea"},{"key":"1299_CR4","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1177\/11206721231199155","volume":"34","author":"SP Pradhan","year":"2024","unstructured":"Pradhan SP, Sadiq SN, Cartes C, Babakinejad P, Ball S, Reynolds NJ, et al. Dupilumab induced ocular surface disease: a prospective case series. Eur J Ophthalmol. 2024;34:691\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"1299_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/bjd\/ljae344","volume":"191","author":"MR Ardern-Jones","year":"2024","unstructured":"Ardern-Jones MR, Brown SJ, Flohr C, Hossain P, Irvine AD, Johnston GA, et al. An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024. Br J Dermatol. 2024;191:865\u201385.","journal-title":"Br J Dermatol"},{"key":"1299_CR6","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1111\/all.15717","volume":"78","author":"R Achten","year":"2023","unstructured":"Achten R, Thijs J, van der Wal M, van Luijk C, de Graaf D, Bakker D, et al. Dupilumab-associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis. Allergy. 2023;78:2266\u201376.","journal-title":"Allergy"},{"key":"1299_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/ICO.0000000000002461","volume":"40","author":"A Bohner","year":"2021","unstructured":"Bohner A, Topham C, Strunck J, Haynes D, Brazil M, Clements J, et al. Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up. Cornea. 2021;40:584\u20139.","journal-title":"Cornea"},{"key":"1299_CR8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.alit.2020.02.006","volume":"69","author":"N Katoh","year":"2020","unstructured":"Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et al. Japanese guidelines for atopic dermatitis 2020. Allergol Int. 2020;69:356\u201369.","journal-title":"Allergol Int"},{"key":"1299_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/ACI.0000000000000376","volume":"17","author":"B Cabanillas","year":"2017","unstructured":"Cabanillas B, Brehler A-C, Novak N. Atopic dermatitis phenotypes and the need for personalized medicine. Curr Opin Allergy Clin Immunol. 2017;17:309\u201315.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4S","key":"1299_CR10","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","volume":"139","author":"PM Brunner","year":"2017","unstructured":"Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65\u201376.","journal-title":"J Allergy Clin Immunol"},{"key":"1299_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","volume":"48","author":"E Guttman-Yassky","year":"2017","unstructured":"Guttman-Yassky E, Krueger J. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68\u201373.","journal-title":"Curr Opin Immunol"},{"key":"1299_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143:1\u201311.","journal-title":"J Allergy Clin Immunol"},{"key":"1299_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/ni805","volume":"3","author":"V Soumelis","year":"2002","unstructured":"Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3:673\u201380.","journal-title":"Nat Immunol"},{"key":"1299_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nature10329","volume":"477","author":"MC Siracusa","year":"2011","unstructured":"Siracusa MC, Saenz SA, Hill DA, Kim BS, Headley MB, Doering TA, et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature. 2011;477:229\u201333.","journal-title":"Nature"},{"key":"1299_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/jid.2014.401","volume":"135","author":"BS Kim","year":"2015","unstructured":"Kim BS. Innate lymphoid cells in the skin. J Invest Dermatol. 2015;135:673\u20138.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1299_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","volume":"8","author":"AB Fishbein","year":"2020","unstructured":"Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91\u2013101.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1299_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","volume":"94","author":"D Tha\u00e7i","year":"2019","unstructured":"Tha\u00e7i D, Simpson EL, Deleuran M, Kataoka Y, Chen Z, Gadkari A, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94:266\u201375.","journal-title":"J Dermatol Sci"},{"key":"1299_CR18","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287\u2013303.","journal-title":"Lancet"},{"key":"1299_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","volume":"84","author":"AS Halling","year":"2021","unstructured":"Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84:139\u201347.","journal-title":"J Am Acad Dermatol"},{"key":"1299_CR20","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jaip.2019.10.011","volume":"8","author":"K Fukuda","year":"2020","unstructured":"Fukuda K, Ebihara N, Kishimoto T, Fukushima A. Amelioration of conjunctival giant papillae by dupilumab in patients with atopic keratoconjunctivitis. J Allergy Clin Immunol Pract. 2020;8:1152\u20135.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1299_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.anai.2022.05.031","volume":"129","author":"J Chen","year":"2022","unstructured":"Chen J, Bielory L. Atopic keratoconjunctivitis alleviated with dupilumab. Ann Allergy Asthma Immunol. 2022;129:375\u20136.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1299_CR22","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/ceo.14142","volume":"50","author":"M-C Tsui","year":"2022","unstructured":"Tsui M-C, Chiang B-L, Wang I-J. Successful treatment and prevention of the recurrence of refractory vernal keratoconjunctivitis with dupilumab. Clin Exp Ophthalmol. 2022;50:1100\u20133.","journal-title":"Clin Exp Ophthalmol"},{"key":"1299_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"181","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181:459\u201373.","journal-title":"Br J Dermatol"},{"key":"1299_CR24","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335\u201348.","journal-title":"N Engl J Med"},{"key":"1299_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","volume":"387","author":"D Tha\u00e7i","year":"2016","unstructured":"Tha\u00e7i D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387:40\u201352.","journal-title":"Lancet"},{"key":"1299_CR26","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (Liberty AD CAF\u00c9). Br J Dermatol. 2018;178:1083\u2013101.","journal-title":"Br J Dermatol"},{"key":"1299_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm M, Simpson EL, Tha\u00e7i D, Bissonnette R, Lacour J-P, Beissert S, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:131\u201343.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1299_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","volume":"23","author":"LA Beck","year":"2022","unstructured":"Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393\u2013408.","journal-title":"Am J Clin Dermatol"},{"key":"1299_CR29","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400:908\u201319.","journal-title":"Lancet"},{"key":"1299_CR30","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83:1282\u201393.","journal-title":"J Am Acad Dermatol"},{"key":"1299_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156:44\u201356.","journal-title":"JAMA Dermatol"},{"key":"1299_CR32","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.alit.2024.04.006","volume":"73","author":"M Ebisawa","year":"2024","unstructured":"Ebisawa M, Kataoka Y, Tanaka A, Nagao M, Laws E, Nortensen E, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled phase 3 study. Allergol Int. 2024;73:532\u201342.","journal-title":"Allergol Int"},{"key":"1299_CR33","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1007\/s12325-023-02573-3","volume":"40","author":"E Hirai","year":"2023","unstructured":"Hirai E, Haruki T, Baba T, Miyazaki D. Analyses of dupilumab-related ocular adverse drug reactions using the WHO\u2019s vigibase. Adv Ther. 2023;40:3830\u201356.","journal-title":"Adv Ther"},{"key":"1299_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/cia2.12303","volume":"60","author":"H Saeki","year":"2023","unstructured":"Saeki H, Fujita H, Suzuki K, Arima K. Safety and effectiveness of dupilumab in the real-world treatment of atopic dermatitis in Japan: 1-year interim analysis from a post-marketing surveillance. J Cutan Immunol Allergy. 2023;60:78\u201387.","journal-title":"J Cutan Immunol Allergy"},{"key":"1299_CR35","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.jaip.2020.09.042","volume":"9","author":"R Achten","year":"2021","unstructured":"Achten R, Bakker D, Ariens L, Lans A, Thijs J, van der Schaft J, et al. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9:1389\u201392.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1299_CR36","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjd.18179","volume":"182","author":"LEM De Wijs","year":"2020","unstructured":"De Wijs LEM, Bosma AL, Erier NS, Hollestein LM, Gerbens LAA, Middelkamp-Hup MA, et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol. 2020;182:418\u201326.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1299_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","volume":"81","author":"S Faiz","year":"2019","unstructured":"Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz J-D, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"1299_CR38","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/jdv.18932","volume":"37","author":"I Costedoat","year":"2023","unstructured":"Costedoat I, Wallaert M, Gaultier A, Vasseur R, Vanhaecke C, Viguier M, et al. Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2023;37:1056\u201363.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1299_CR39","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjd.18958","volume":"183","author":"S Abraham","year":"2020","unstructured":"Abraham S, Haufe E, Harder I, Heratizadeh A, Kleinheinz A, Wollenberg A, et al. Implementation of dupilumab in routine care of atopic eczema: results from the German national registry TREATgermany. Br J Dermatol. 2020;183:382\u20134.","journal-title":"Br J Dermatol"},{"key":"1299_CR40","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/bjd.21794","volume":"187","author":"D St\u00f6lzl","year":"2022","unstructured":"St\u00f6lzl D, Sander N, Heratizadeh A, Haufe E, Harder I, Abraham S, et al. Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry. Br J Dermatol. 2022;187:1022\u20134.","journal-title":"Br J Dermatol"},{"key":"1299_CR41","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaad.2024.04.026","volume":"91","author":"J Zhang","year":"2024","unstructured":"Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn MLE, Spekhorst LS, et al. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay registry. J Am Acad Dermatol. 2024;91:300\u201311.","journal-title":"J Am Acad Dermatol"},{"key":"1299_CR42","doi-asserted-by":"publisher","first-page":"201","DOI":"10.18176\/jiaci.0481","volume":"30","author":"E Nettis","year":"2020","unstructured":"Nettis E, Bonzano L, Patella V, Detoraki A, Trerotoli P, Lombardo C, et al. Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Investig Allergol Clin Immunol. 2020;30:201\u20134.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1299_CR43","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1080\/09273948.2018.1533567","volume":"27","author":"E Shen","year":"2019","unstructured":"Shen E, Xie K, Jwo K, Smith J, Mosaed S. Dupilumab-induced follicular conjunctivitis. Ocul Immunol Inflamm. 2019;27:1339\u201341.","journal-title":"Ocul Immunol Inflamm"},{"key":"1299_CR44","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","volume":"8","author":"A Maudinet","year":"2019","unstructured":"Maudinet A, Law-Koune S, Duretz C, Lasek A, Modiano P, Tran THC. Ocular surface diseases induced by dupilumab in severe atopic dermatitis. Ophthalmol Ther. 2019;8:485\u201390.","journal-title":"Ophthalmol Ther"},{"key":"1299_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101528","volume":"26","author":"AK Reddy","year":"2022","unstructured":"Reddy AK, Hauswirth SG, Gregory DG, Liao SD, Palestine AG. Dupilumab-associated cicatrizing ocular disease. Am J Ophthalmol Case Rep. 2022;26:101528.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"1299_CR46","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","volume":"154","author":"RM Levine","year":"2018","unstructured":"Levine RM, Tattersall IW, Gaudio PA, King BA. Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management. JAMA Dermatol. 2018;154:1485\u20136.","journal-title":"JAMA Dermatol"},{"key":"1299_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2019.100550","volume":"16","author":"SA Paulose","year":"2019","unstructured":"Paulose SA, Sherman SW, Dagi Glass LR, Suh LH. Dupilumab-associated blepharoconjunctivitis. Am J Ophthalmol Case Rep. 2019;16:100550.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"1299_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100848","volume":"19","author":"G Li","year":"2020","unstructured":"Li G, Berkenstock M, Soiberman U. Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis. Am J Ophthalmol Case Rep. 2020;19:100848.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"1299_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2021-000947","volume":"7","author":"M H\u00e9bert","year":"2022","unstructured":"H\u00e9bert M, Qi SR, You E, Mercier M, Laughrea P-A. Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series. BMJ Open Ophthalmol. 2022;7:e000947.","journal-title":"BMJ Open Ophthalmol"},{"key":"1299_CR50","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jdcr.2018.10.016","volume":"5","author":"MJ Zirwas","year":"2019","unstructured":"Zirwas MJ, Wulff K, Beckman K. Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): a novel case report. JAAD Case Rep. 2019;5:34\u20136.","journal-title":"JAAD Case Rep"},{"key":"1299_CR51","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/ICO.0000000000002854","volume":"41","author":"M Phylactou","year":"2022","unstructured":"Phylactou M, Jabbbour S, Ahmad S, Vasquez-Perez A. Corneal perforation in patients under treatment with dupilumab for atopic dermatitis. Cornea. 2022;41:981\u20135.","journal-title":"Cornea"},{"key":"1299_CR52","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1080\/09273948.2023.2182325","volume":"32","author":"R Achten","year":"2024","unstructured":"Achten R, van Luijk C, Thijs J, Drylewicz J, Delemarre E, Nierkens S, et al. Non-infectious uveitis secondary to dupilumab treatment in atopic dermatitis patients shows a pro-inflammatory molecular profile. Ocul Immunol Inflamm. 2024;32:1150\u20134.","journal-title":"Ocul Immunol Inflamm"},{"key":"1299_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2229466","volume":"34","author":"S Zhang","year":"2023","unstructured":"Zhang S, Lu L, Feng J, Hu Z, Song H, Yang L, et al. Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient. J Dermatolog Treat. 2023;34:2229466.","journal-title":"J Dermatolog Treat"},{"key":"1299_CR54","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/bjd.17538","volume":"180","author":"DS Bakker","year":"2019","unstructured":"Bakker DS, Ariens LFM, van Luijk C, van der Schaft J, Thijs JL, Schuttelaar MLA, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180:1248\u20139.","journal-title":"Br J Dermatol"},{"key":"1299_CR55","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaci.2003.11.025","volume":"113","author":"S Romagnari","year":"2004","unstructured":"Romagnari S. Immunologic influences on allergy and the TH1\/TH2 balance. J Allergy Clin Immunol. 2004;113:395\u2013400.","journal-title":"J Allergy Clin Immunol"},{"key":"1299_CR56","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1111\/all.15064","volume":"76","author":"DS Bakker","year":"2021","unstructured":"Bakker DS, Ter Linde JJM, Amini MM, Ari\u00ebns LFM, van Luijk CM, de Bruin-Weller MS, et al. Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1\/T17 cytokines: a case series study. Allergy. 2021;76:3814\u20137.","journal-title":"Allergy"},{"key":"1299_CR57","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/ACI.0000000000000098","volume":"14","author":"DA Dartt","year":"2014","unstructured":"Dartt DA, Masli S. Conjunctival epithelial and goblet cell function in chronic inflammation and ocular allergic inflammation. Curr Opin Allergy Clin Immunol. 2014;14:464\u201370.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1299_CR58","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.3.29","volume":"9","author":"BP Barnett","year":"2020","unstructured":"Barnett BP, Afshari NA. Dupilumab-associated mucin deficiency (DAMD). Transl Vis Sci Technol. 2020;9:29.","journal-title":"Transl Vis Sci Technol"},{"key":"1299_CR59","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/all.15326","volume":"77","author":"PM Hansen","year":"2022","unstructured":"Hansen PM, Tollenaere MAX, Hedengran A, Heegaard S, Amoudruz P, R\u00f8pke M, et al. IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro. Allergy. 2022;77:2555\u20138.","journal-title":"Allergy"},{"key":"1299_CR60","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/02713680500196715","volume":"30","author":"M Dogru","year":"2005","unstructured":"Dogru M, Asano-Kato N, Tanaka M, Igarashi A, Shimmura S, Shimazaki J, et al. Ocular surface and MUC5AC alterations in atopic patients with corneal shield ulcer. Curr Eye Res. 2005;30:897\u2013908.","journal-title":"Curr Eye Res"},{"key":"1299_CR61","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9914786","volume":"2021","author":"M Horinaka","year":"2021","unstructured":"Horinaka M, Shoji J, Tomioka A, Tonozuka Y, Inada N, Yamagami S. Alterations in mucin-associated gene expression on the ocular surface in active and stable stages of atopic and vernal keratoconjunctivitis. J Ophthalmol. 2021;2021:9914786.","journal-title":"J Ophthalmol"},{"key":"1299_CR62","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"T Korn","year":"2009","unstructured":"Korn T, Bettelli E, Oukka M, Kuchroo V. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485\u2013517.","journal-title":"Annu Rev Immunol"},{"key":"1299_CR63","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/17476348.2019.1666002","volume":"13","author":"R Ramakrishnan","year":"2019","unstructured":"Ramakrishnan R, Heialy SAl, Hamid Q. Role of IL-17 in asthma pathogenesis and its implications for the clinic. Expert Rev Respir Med. 2019;13:1057\u201368.","journal-title":"Expert Rev Respir Med"},{"key":"1299_CR64","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000211382","volume":"149","author":"H Wakashin","year":"2009","unstructured":"Wakashin H, Hirose K, Iwamoto I, Nakajima H. Role of IL-23-Th17 cell axis in allergic airway inflammation. Int Arch Allergy Immunol. 2009;149:108\u201312.","journal-title":"Int Arch Allergy Immunol"},{"key":"1299_CR65","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/jid.2008.111","volume":"128","author":"C Koga","year":"2008","unstructured":"Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128:2625\u201330.","journal-title":"J Invest Dermatol"},{"key":"1299_CR66","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/all.16045","volume":"79","author":"K Thormann","year":"2024","unstructured":"Thormann K, L\u00fcthi A-S, Deniau F, Heider A, Cazzaniga S, Radonjic-Hoesli S, et al. Dupilumab-associated ocular surface disease is characterized by a shift from Th2\/Th17 toward Th1\/Th17 inflammation. Allergy. 2024;79:937\u201348.","journal-title":"Allergy"},{"key":"1299_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-381300-8.00001-0","volume":"107","author":"GF Sonnenberg","year":"2010","unstructured":"Sonnenberg GF, Fouser LA, Artis D. Functional biology of IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol. 2010;107:1\u201329.","journal-title":"Adv Immunol"},{"key":"1299_CR68","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/eji.200535503","volume":"36","author":"K Wolk","year":"2006","unstructured":"Wolk K, Witte E, Wallace E, D\u00f6cke W-D, Kunz S, Asadullah K, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36:1309\u201323.","journal-title":"Eur J Immunol"},{"key":"1299_CR69","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","volume":"123","author":"KE Nograles","year":"2009","unstructured":"Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, et al. IL-22-producing \u201cT22\u201d T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009;123:1244\u201352.","journal-title":"J Allergy Clin Immunol"},{"key":"1299_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cells13161398","volume":"13","author":"J Laska","year":"2024","unstructured":"Laska J, Tota M, Lacwik J, Sedek L, Gomulka K. IL-22 in atopic dermatitis. Cells. 2024;13:1398.","journal-title":"Cells"},{"key":"1299_CR71","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/apm.13221","volume":"130","author":"DV Lopez","year":"2022","unstructured":"Lopez DV, Kongsbak-Wismann M. Role of IL-22 in homeostasis and diseases of the skin. APMIS. 2022;130:314\u201322.","journal-title":"APMIS"},{"key":"1299_CR72","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jdermsci.2010.08.013","volume":"61","author":"S Hayashida","year":"2011","unstructured":"Hayashida S, Uchi H, Takeuchi S, Esaki H, Moroi Y, Furue M. Significant correlation of serum IL-22 levels with CCL17 levels in atopic dermatitis. J Dermatol Sci. 2011;61:78\u20139.","journal-title":"J Dermatol Sci"},{"key":"1299_CR73","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.alit.2024.10.002","volume":"74","author":"R Adachi","year":"2025","unstructured":"Adachi R, Shoji J, Hirota A, Tomioka A, Hayama K, Inada N, et al. Diagnostic utility of interleukin-22 in ocular surface testing for dupilumab-associated ocular surface disease. Allergol Int. 2025;74:330\u20132.","journal-title":"Allergol Int"},{"key":"1299_CR74","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1038\/s41467-024-46540-0","volume":"15","author":"C Bangert","year":"2024","unstructured":"Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine JP, Pilz M, et al. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun. 2024;15:2839.","journal-title":"Nat Commun"},{"key":"1299_CR75","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/09546634.2019.1624683","volume":"32","author":"HD Heibel","year":"2021","unstructured":"Heibel HD, Hendricks AJ, Foshee JP, Shi VY. Rosacea associated with dupilumab therapy. J Dermatolog Treat. 2021;32:114\u20136.","journal-title":"J Dermatolog Treat"},{"key":"1299_CR76","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/j.immuni.2022.08.001","volume":"55","author":"RR Ricardo-Gonzalez","year":"2022","unstructured":"Ricardo-Gonzalez RR, Kotas ME, O\u2019Leary CE, Singh K, Damsky W, Liao C, et al. Innate type 2 immunity controls hair follicle commensalism by Demodex mites. Immunity. 2022;55:1891\u2013908.","journal-title":"Immunity"},{"key":"1299_CR77","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/bjd.16330","volume":"178","author":"JP Thyssen","year":"2018","unstructured":"Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Br J Dermatol. 2018;178:1220.","journal-title":"Br J Dermatol"},{"key":"1299_CR78","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2147\/OPTH.S336978","volume":"16","author":"Z Tauqeer","year":"2022","unstructured":"Tauqeer Z, Jinno SE, Chung CW, Massaro-Giordano M, Bunya VY. Clinical characteristics and treatment for dupilumab-related ocular complications in atopic dermatitis patients. Clin Ophthalmol. 2022;16:947\u201358.","journal-title":"Clin Ophthalmol"},{"key":"1299_CR79","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.3390\/biomedicines11123104","volume":"11","author":"F Serino","year":"2023","unstructured":"Serino F, Dattilo V, Cennamo M, Roszkowska AM, Gola M, Magliulo M, et al. Dupilumab-associated blepharoconjunctivitis: clinical and morphological aspects. Biomedicines. 2023;11:3104.","journal-title":"Biomedicines"},{"key":"1299_CR80","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1007\/s12325-025-03209-4","volume":"42","author":"P Asbell","year":"2025","unstructured":"Asbell P, Akpek E, Chamberlain W, Chen Z, Lawless E, Van Spall M, et al. Conjunctivitis in adults with atopic dermatitis treated with dupilumab: an observational study of clinical characteristics, symptomatology, and treatment. Adv Ther. 2025;42:3285\u2013305.","journal-title":"Adv Ther"},{"key":"1299_CR81","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.alit.2018.12.012","volume":"68","author":"K Fukuda","year":"2019","unstructured":"Fukuda K, Ishida W, Kishimoto T, Fukushima A. Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis. Allergol Int. 2019;68:383\u20134.","journal-title":"Allergol Int"},{"key":"1299_CR82","first-page":"303","volume":"13","author":"F Vingopoulos","year":"2020","unstructured":"Vingopoulos F, RLazzaro D. Dupilumab-associated blepharoconjunctivitis with giant papillae. Int Med Case Rep J. 2020;13:303\u20135.","journal-title":"Int Med Case Rep J"},{"key":"1299_CR83","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.alit.2020.05.003","volume":"69","author":"J Shoji","year":"2020","unstructured":"Shoji J. Ocular allergy test and biomarkers on the ocular surface: clinical test for evaluating the ocular surface condition in allergic conjunctival diseases. Allergol Int. 2020;69:496\u2013504.","journal-title":"Allergol Int"},{"key":"1299_CR84","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/exd.14859","volume":"32","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Di Nardo L, Gori N, Antonelli F, Pinto L, Cuffaro G, et al. Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis. Exp Dermatol. 2023;32:1531\u20137.","journal-title":"Exp Dermatol"},{"key":"1299_CR85","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/cea.14269","volume":"53","author":"R Achten","year":"2023","unstructured":"Achten R, Thijs J, van Luijk C, Knol E, Delemarre E, de Graaf M, et al. Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients. Clin Exp Allergy. 2023;53:239\u201343.","journal-title":"Clin Exp Allergy"},{"key":"1299_CR86","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13223-022-00727-6","volume":"18","author":"R Adachi","year":"2022","unstructured":"Adachi R, Shoji J, Hirota A, Tomioka A, Tonozuka Y, Inada N, et al. Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report. Allergy Asthma Clin Immunol. 2022;18:89.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1299_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100340","volume":"4","author":"VK Patra","year":"2023","unstructured":"Patra VK, Woltsche N, Cerpes U, Bokanovic D, Repelnig M, Joshi A, et al. Persistent neutrophil infiltration and unique ocular surface microbiome typify dupilumab-associated conjunctivitis in patients with atopic dermatitis. Ophthalmol Sci. 2023;4:100340.","journal-title":"Ophthalmol Sci."},{"key":"1299_CR88","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","volume":"6","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegr\u00e4ber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6:1778\u201380.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1299_CR89","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2340\/00015555-3121","volume":"99","author":"LU Ivert","year":"2019","unstructured":"Ivert LU, Wahlgren C-F, Ivert L, Lundqvist M, Bradley M. Eye complications during dupilumab treatment for severe atopic dermatitis. Acta Derm Venereol. 2019;99:375\u20138.","journal-title":"Acta Derm Venereol"},{"key":"1299_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101309","volume":"25","author":"F Di Staso","year":"2022","unstructured":"Di Staso F, Lambiase A, Di Staso S, Gattazzo I, Ciancaglini M, Scuderi G. Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis. Am J Ophthalmol Case Rep. 2022;25:101309.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"1299_CR91","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","volume":"35","author":"MZ Popiela","year":"2021","unstructured":"Popiela MZ, Barbara R, Turnbull AMJ, Corden E, Martinez-Falero BS, O\u2019Driscoll D, et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye (Lond). 2021;35:3277\u201384.","journal-title":"Eye (Lond)"},{"key":"1299_CR92","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/jdv.15608","volume":"33","author":"JP Thyssen","year":"2019","unstructured":"Thyssen JP, de Bruin-Weller MS, Paller AS, Leshem YA, Vestergaard C, Deleuran M, et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy: International Eczema Council survey and opinion. J Eur Acad Dermatol Venereol. 2019;33:1224\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1299_CR93","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/ajd.13924","volume":"63","author":"P Foley","year":"2022","unstructured":"Foley P, Kerdraon YA, Hogden JP, Shumack S, Spelman L, Sebaratnam DF, et al. Dupilumab-associated ocular surface disease: an interdisciplinary decision framework for prescribers in the Australian setting. Australas J Dermatol. 2022;63:421\u201336.","journal-title":"Australas J Dermatol"},{"key":"1299_CR94","doi-asserted-by":"publisher","DOI":"10.4414\/SMW.2021.w30020","volume":"151","author":"Y Guex-Crosier","year":"2021","unstructured":"Guex-Crosier Y, Di-Lucca J, H\u00e4usermann P, Laffitte E, Saulite I, Schmid-Grendelmeier P, et al. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients. Swiss Med Wkly. 2021;151:w30020.","journal-title":"Swiss Med Wkly"},{"key":"1299_CR95","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.alit.2024.10.004","volume":"74","author":"J Shoji","year":"2025","unstructured":"Shoji J, Asada Y, Adachi R, Inada N, Uchio E, Kataoka Y, et al. Questionnaire survey among ophthalmic allergists on dupilumab-associated ocular surface disease in Japan. Allergol Int. 2025;74:333\u20135.","journal-title":"Allergol Int"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01299-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01299-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01299-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:02:21Z","timestamp":1772172141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01299-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01299-9","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J. Shoji, advisory board member (Santen), lecture fees (Santen, Senju, Rohto Nitten, AbbVie); N. Ebihara, Research grants (Santen).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}